Victoria Moghildea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Victoria Moghildea has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Oleg Arnaut
Department of Human Physiology and Biophysics, Nicolae Testemitanu State University of Medicine and Pharmacy, MD-2004 Chisinau, Moldova
4 shared publications - Serghei Sandru
Institute of Emergency Medicine
3 shared publications - Ion Grabovschi
Nicolae Testemitanu State University of Medicine and Pharmacy
2 shared publications - Ivan Civirjic2 shared publications
- Natalia Cernei
IMSP Institutul de Medicină Urgentă; IP Universitatea de Stat de Medicină și Farmacie “Nicolae Testemițanu
2 shared publications - Ruslan Baltaga
Department of Anesthesiology and Intensive Care Nr. 1, Nicolae Testemitanu State University of Medicine and Pharmacy, MD-2004 Chisinau, Moldova
2 shared publications
Latest Publications
- 27 September 2025
- Published by Springer Nature
- p. 187-197
Predictive Value of Biochemical Markers on Mortality in Hospitalized COVID-19 Patients in Intensive Care Units
- 27 September 2025
- Published by Springer Nature
- p. 187-197
Predictive Value of Biochemical Markers on Mortality in Hospitalized COVID-19 Patients in Intensive Care Units
- 1 March 2025
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 12 (1) , 61-68
Artificial intelligence-based techniques for predicting outcomes in COVID-19 patients
Introduction. Currently, extensive research has shown that almost all published prediction models are poorly studied and have significant limitations, leading to their predictive performance often being overestimated. Additionally, there is still no universally accepted scoring system, primarily due to the need for adaptation to heterogeneous patient samples (including patient numbers, clinical profiles, and risk factors) and/or ongoing differences in the organization of healthcare systems across various countries. Materials and methods. This is a narrative literature review. A bibliographic search was conducted in the PubMed, Hinari, SpringerLink, National Center for Biotechnology Information, and Medline databases. Articles published between 2000 and 2024 were selected based on keyword combinations such as “artificial intelligence”, “prediction model”, “algorithm”, “machine learning”, and “COVID-19”. Information on machine learning predictive models was selected and processed to identify characteristics that can be used to predict diagnosis, severity, length of hospital stay, ICU admission, treatment, vaccination, and mortality in COVID-19 patients. After processing the data according to the search criteria, 125 full-text articles were identified. The final bibliography includes 52 relevant sources, which were considered representative of the literature on this synthesis article topic. Results. Artificial intelligence techniques are increasingly being used to predict outcomes in COVID-19 patients, particularly in estimating mortality among individuals infected with SARS-CoV-2, which can rapidly and effectively support clinical decision-making. According to the analysis of multiple studies, strong predictors of mortality in COVID-19 patients include advanced age, male gender, comorbidities, reduced levels of calcium, albumin, red blood cells, and oxygen saturation, as well as lymphopenia, elevated blood urea nitrogen, creatinine, lactate dehydrogenase, D-dimers, neutrophils, interleukin-6, procalcitonin, bilirubin, ferritin, aspartate aminotransferase, and troponin. Conclusions. Artificial intelligence techniques provide potential advantages over conventional assessment methods. The information obtained from machine learning and deep learning algorithms, including easily accessible and interpretable data, can assist healthcare workers in making accurate decisions for the appropriate and timely care of COVID- 19 patients. This can improve patient outcomes, reduce the burden on healthcare systems, and ultimately decrease mortality rates.
- 1 March 2025
- Published by Periodic Publication Moldovan Journal of Health Sciences in Moldovan Journal of Health Sciences
- Vol. 12 (1) , 61-68
Artificial intelligence-based techniques for predicting outcomes in COVID-19 patients
Introduction. Currently, extensive research has shown that almost all published prediction models are poorly studied and have significant limitations, leading to their predictive performance often being overestimated. Additionally, there is still no universally accepted scoring system, primarily due to the need for adaptation to heterogeneous patient samples (including patient numbers, clinical profiles, and risk factors) and/or ongoing differences in the organization of healthcare systems across various countries. Materials and methods. This is a narrative literature review. A bibliographic search was conducted in the PubMed, Hinari, SpringerLink, National Center for Biotechnology Information, and Medline databases. Articles published between 2000 and 2024 were selected based on keyword combinations such as “artificial intelligence”, “prediction model”, “algorithm”, “machine learning”, and “COVID-19”. Information on machine learning predictive models was selected and processed to identify characteristics that can be used to predict diagnosis, severity, length of hospital stay, ICU admission, treatment, vaccination, and mortality in COVID-19 patients. After processing the data according to the search criteria, 125 full-text articles were identified. The final bibliography includes 52 relevant sources, which were considered representative of the literature on this synthesis article topic. Results. Artificial intelligence techniques are increasingly being used to predict outcomes in COVID-19 patients, particularly in estimating mortality among individuals infected with SARS-CoV-2, which can rapidly and effectively support clinical decision-making. According to the analysis of multiple studies, strong predictors of mortality in COVID-19 patients include advanced age, male gender, comorbidities, reduced levels of calcium, albumin, red blood cells, and oxygen saturation, as well as lymphopenia, elevated blood urea nitrogen, creatinine, lactate dehydrogenase, D-dimers, neutrophils, interleukin-6, procalcitonin, bilirubin, ferritin, aspartate aminotransferase, and troponin. Conclusions. Artificial intelligence techniques provide potential advantages over conventional assessment methods. The information obtained from machine learning and deep learning algorithms, including easily accessible and interpretable data, can assist healthcare workers in making accurate decisions for the appropriate and timely care of COVID- 19 patients. This can improve patient outcomes, reduce the burden on healthcare systems, and ultimately decrease mortality rates.
- 30 September 2024
- Published by Institutul National de Cercetare Dezvoltare Medico-Militara "Cantacuzino" in Romanian Archives of Microbiology and Immunology
- Vol. 83 (3) , 164-172
SEROLOGICAL BIOMARKERS IN PREDICTING THE SEVERITY AND OUTCOMES OF COVID-19 PATIENTS
Biomarkers have always played a crucial role in clinical decision-making. The study aimed to identify the latest findings on the role of various biomarkers in assessing the severity and mortality of COVID-19 patients. To select bibliographic sources in advance, various filters were applied in more stages. Relevant information was collected, organized, evaluated, and summarized, emphasizing key aspects of the current understanding of biomarkers. Based on the search criteria, 275 articles focused on biomarkers' informative role. Elevated procalcitonin in COVID-19 patients is commonly used to assess disease severity and predict mortality. Monitoring C-reactive protein is crucial for early diagnosis, identifying severe cases, and ensuring appropriate management of COVID-19 patients, even prior to the progression of the disease and the onset of clinical and imaging manifestations. Serum levels of D-dimers and elevated lactate dehydrogenase activity are associated with the severity of SARS-CoV-2 infection and are considered a valuable prognostic marker for mortality in this patient group. However, there is significant heterogeneity among studies regarding the association between D-dimer and COVID-19 outcomes, possibly due to variability in the accuracy and reliability of parameter measurements depending on the kit manufacturer. There is no consensus on the optimal value of the neutrophil-lymphocyte ratio and its association with the severity and mortality of COVID-19 patients. In various studies, a neutrophil-lymphocyte ratio value of ≥ 6.0, ≥ 6.5, and ≥ 8 points have been associated with an increased 28-day mortality in COVID-19 patients.
- 30 September 2024
- Published by Institutul National de Cercetare Dezvoltare Medico-Militara "Cantacuzino" in Romanian Archives of Microbiology and Immunology
- Vol. 83 (3) , 164-172
SEROLOGICAL BIOMARKERS IN PREDICTING THE SEVERITY AND OUTCOMES OF COVID-19 PATIENTS
Biomarkers have always played a crucial role in clinical decision-making. The study aimed to identify the latest findings on the role of various biomarkers in assessing the severity and mortality of COVID-19 patients. To select bibliographic sources in advance, various filters were applied in more stages. Relevant information was collected, organized, evaluated, and summarized, emphasizing key aspects of the current understanding of biomarkers. Based on the search criteria, 275 articles focused on biomarkers' informative role. Elevated procalcitonin in COVID-19 patients is commonly used to assess disease severity and predict mortality. Monitoring C-reactive protein is crucial for early diagnosis, identifying severe cases, and ensuring appropriate management of COVID-19 patients, even prior to the progression of the disease and the onset of clinical and imaging manifestations. Serum levels of D-dimers and elevated lactate dehydrogenase activity are associated with the severity of SARS-CoV-2 infection and are considered a valuable prognostic marker for mortality in this patient group. However, there is significant heterogeneity among studies regarding the association between D-dimer and COVID-19 outcomes, possibly due to variability in the accuracy and reliability of parameter measurements depending on the kit manufacturer. There is no consensus on the optimal value of the neutrophil-lymphocyte ratio and its association with the severity and mortality of COVID-19 patients. In various studies, a neutrophil-lymphocyte ratio value of ≥ 6.0, ≥ 6.5, and ≥ 8 points have been associated with an increased 28-day mortality in COVID-19 patients.
- 1 April 2023
- Published by State Enterprise "Revista Curier Medical" in The Moldovan Medical Journal
- Vol. 66 (1) , 66-76
Predictable severity biomarkers in Covid-19
Introduction: The recorded studies suggest that there is clear evidence-based association between various laboratory biomarkers and COVID-19 disease severity. These marker levels reflect the intensity of the cytokine-mediated hyperinflammatory response, which is strongly associated with a poor outcome of SARS-CoV-2 infection. Conclusions: C-reactive protein is not only a systemic inflammatory marker, but also an important regulator of inflammatory processes. The level of this protein is positively correlated and can be widely used to predict the severity, prognosis and mortality in COVID-19 patients, additionally to vital signs monitoring, supportive care, oxygen therapy, ventilation and circulatory support. Procalcitonin is an indicator of disease severity, which can facilitate timely clinical decision-making, and determination of procalcitonin levels during COVID-19 patients’ follow-up, as well as being used in assessing risk, predicting prognosis, and improving patient survival. The assessment of hematological laboratory parameters upon admission, which help in differentiating between severe and non-severe cases, high-risk and low-risk cases of mortality, allows raising awareness, monitoring and timely treatment of patients with COVID-19, as well as their early improvement of clinical condition. Inflammatory biochemical and hemocytometric measures are feasible, easily interpretable, and widely available biomarkers in most healthcare settings, favorable for being used in treatment and severity determination, in predicting clinical outcomes, and in the prognosis of patients with COVID-19. However, the assessment of the accuracy of these biomarkers needs to be determined in further more relevant worldwide studies, showing a more precise design, more accurate performance, and having larger sample sizes.
- 1 April 2023
- Published by State Enterprise "Revista Curier Medical" in The Moldovan Medical Journal
- Vol. 66 (1) , 66-76
Predictable severity biomarkers in Covid-19
Introduction: The recorded studies suggest that there is clear evidence-based association between various laboratory biomarkers and COVID-19 disease severity. These marker levels reflect the intensity of the cytokine-mediated hyperinflammatory response, which is strongly associated with a poor outcome of SARS-CoV-2 infection. Conclusions: C-reactive protein is not only a systemic inflammatory marker, but also an important regulator of inflammatory processes. The level of this protein is positively correlated and can be widely used to predict the severity, prognosis and mortality in COVID-19 patients, additionally to vital signs monitoring, supportive care, oxygen therapy, ventilation and circulatory support. Procalcitonin is an indicator of disease severity, which can facilitate timely clinical decision-making, and determination of procalcitonin levels during COVID-19 patients’ follow-up, as well as being used in assessing risk, predicting prognosis, and improving patient survival. The assessment of hematological laboratory parameters upon admission, which help in differentiating between severe and non-severe cases, high-risk and low-risk cases of mortality, allows raising awareness, monitoring and timely treatment of patients with COVID-19, as well as their early improvement of clinical condition. Inflammatory biochemical and hemocytometric measures are feasible, easily interpretable, and widely available biomarkers in most healthcare settings, favorable for being used in treatment and severity determination, in predicting clinical outcomes, and in the prognosis of patients with COVID-19. However, the assessment of the accuracy of these biomarkers needs to be determined in further more relevant worldwide studies, showing a more precise design, more accurate performance, and having larger sample sizes.
- 1 December 2022
- Published by State Enterprise "Revista Curier Medical" in The Moldovan Medical Journal
- Vol. 65 (2) , 51-58
Factors to consider when assessing the severity of COVID-19
Background: Analysis and evaluation of the multitude of parameters that impact and mirror clinical evolution of COVID-19 infection. Narrative literature review type of study. Bibliographic search of the PubMed database, applying the keywords: ”SARS-CoV-2”, ”COVID-19”, ”risk score”, ”laboratory parameters”, ”pathophysiology”, ”cytokine storm”, ”imaging evaluation”, “outcomes”, “clinical evolution”, which were combined with each other. There were selected English-language publications, in extenso, published in recognized journals from March 2020. Priority in the analysis was given to articles of critical synthesis of literature, randomized studies, those with large samples of patients. One of the clinically important symptoms that reflects severe or critical clinical evolution is persistent fever during the time. The presence of comorbidities, especially associated with obesity, represents a high risk of severe evolution. Proinflammatory, prothrombotic and systemic endothelial damage processes are represented by changes in platelet count, lymphocytes, neutrophil / lymphocyte ratio, C-reactive protein, D-dimers, fibrinogen, procalcitonin, urea, creatinine, ALS, AST, interleukin-6 and serum ferritin. Bacterial and fungal infections negatively influence clinical evolution. Common prediction scores have low value in COVID-19 patients and need adaptation. Imaging evaluation identifies the type of lung injury and correlates with the severity degree and outcome. Conclusions: COVID-19 disease caused by SARS-CoV-2 virus includes a multitude of pathophysiological changes that through its mechanism represent a systemic nosology. The complete analysis of all the factors and parameters that can influence its clinical evolution is a basic component of the decision-making steps and treatment approach.
- 1 December 2022
- Published by State Enterprise "Revista Curier Medical" in The Moldovan Medical Journal
- Vol. 65 (2) , 51-58
Factors to consider when assessing the severity of COVID-19
Background: Analysis and evaluation of the multitude of parameters that impact and mirror clinical evolution of COVID-19 infection. Narrative literature review type of study. Bibliographic search of the PubMed database, applying the keywords: ”SARS-CoV-2”, ”COVID-19”, ”risk score”, ”laboratory parameters”, ”pathophysiology”, ”cytokine storm”, ”imaging evaluation”, “outcomes”, “clinical evolution”, which were combined with each other. There were selected English-language publications, in extenso, published in recognized journals from March 2020. Priority in the analysis was given to articles of critical synthesis of literature, randomized studies, those with large samples of patients. One of the clinically important symptoms that reflects severe or critical clinical evolution is persistent fever during the time. The presence of comorbidities, especially associated with obesity, represents a high risk of severe evolution. Proinflammatory, prothrombotic and systemic endothelial damage processes are represented by changes in platelet count, lymphocytes, neutrophil / lymphocyte ratio, C-reactive protein, D-dimers, fibrinogen, procalcitonin, urea, creatinine, ALS, AST, interleukin-6 and serum ferritin. Bacterial and fungal infections negatively influence clinical evolution. Common prediction scores have low value in COVID-19 patients and need adaptation. Imaging evaluation identifies the type of lung injury and correlates with the severity degree and outcome. Conclusions: COVID-19 disease caused by SARS-CoV-2 virus includes a multitude of pathophysiological changes that through its mechanism represent a systemic nosology. The complete analysis of all the factors and parameters that can influence its clinical evolution is a basic component of the decision-making steps and treatment approach.